CAR T cells

DRUG10 trials

Sponsors

Baylor College of Medicine, Uppsala University, Shenzhen Geno-Immune Medical Institute, Memorial Sloan Kettering Cancer Center, Shanghai Cell Therapy Group Co.,Ltd

Conditions

B-Cell LymphomaB-Cell Non-Hodgkin LymphomaB-cell LeukemiaColorectal CancerGastric AdenocarcinomaHodgkin's LymphomaMalignant Pleural Mesothelioma (MPM)Multiple Myeloma

Phase 1

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

RecruitingNCT02917083

Baylor College of MedicineHodgkin's Lymphoma, Non-Hodgkin Lymphoma

Start: 2017-05-08End: 2040-02-01Target: 60Updated: 2026-06-10

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Not yet recruitingNCT03271632

Shenzhen Geno-Immune Medical InstituteMultiple Myeloma

Start: 2026-12-31End: 2030-12-31Target: 20Updated: 2026-08-27

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Active, not recruitingNCT04577326

Memorial Sloan Kettering Cancer CenterMalignant Pleural Mesothelioma (MPM)

Start: 2020-09-30End: 2026-09-30Updated: 2026-07-27

Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors

Shanghai Cell Therapy Group Co.,LtdColorectal Cancer

Start: 2021-11-30End: 2025-01-30Target: 30Updated: 2023-07-17

A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma

RecruitingNCT06734871

Aibin Liang，MD，Ph.D.B-Cell Non-Hodgkin Lymphoma

Start: 2024-12-30End: 2026-07-13Target: 24Updated: 2025-01-03

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

RecruitingNCT06822868

Kai HuB-Cell Non-Hodgkin Lymphoma

Start: 2025-02-10End: 2026-09-30Target: 24Updated: 2025-02-12

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )

Not yet recruitingNCT07032324

Qian WenbinB-Cell Non-Hodgkin Lymphoma

Start: 2025-07-08End: 2026-12-30Target: 27Updated: 2025-06-23

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )

RecruitingNCT07053670

Tongji HospitalB-Cell Non-Hodgkin Lymphoma

Start: 2025-07-09End: 2026-12-30Target: 27Updated: 2025-11-17

Phase 2

CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy

CompletedNCT03068416

Uppsala UniversityB-cell Leukemia, B-Cell Lymphoma

Start: 2017-09-18End: 2021-08-19Updated: 2021-10-20

Phase 3

A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients

RecruitingNCT07103668

Suzhou Immunofoco Biotechnology Co., LtdGastric Adenocarcinoma

Start: 2025-08-06End: 2027-05-31Target: 150Updated: 2025-10-23

Related Papers

Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy.

2023-12-266 citations

Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients

Clinical Cancer Research2023-08-0413 citations

The Role of Asbestos in Global Malignant Mesothelioma

Oncology Times2023-01-03

Phase 1b/2 Study of Autologous CD30.CAR-T Cells in Combination with Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma after Failure of Frontline Therapy (ACTION)

Blood2022-11-153 citations

Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma

Blood2021-11-058 citations

136 ATA3271: An armored, next-generation off-the-shelf, allogeneic, mesothelin-CAR T cell therapy for solid tumors

Regular and Young Investigator Award Abstracts2021-11-011 citations

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

UNC Libraries2021-05-071 citations

A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma

Blood2020-11-056 citations

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

Journal of Clinical Oncology2020-07-23366 citations

Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)

BMJ Open2020-02-0149 citations

CD30‐CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS FOR THERAPY OF HODGKIN LYMPHOMA (HL)

Hematological Oncology2019-06-019 citations

CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL)

Blood2018-11-2926 citations